In brief: Avantogen, Novogen, Peplin, ResMed
Friday, 02 September, 2005
Alastair Hood has resigned as a director of Avantogen (ASX:ACU), formerly Australian Cancer Technology, citing increased corporate and travel commitments with his investment company Bluespire as the reason for his departure.
Dr Graham Kelly has resigned as a director of Novogen (ASX:NRT) to focus on the development and expansion of its US subsidiary companies Glycotex and Marshall Edwards.
Former Queensland premier Wayne Goss will retire as a non-executive director of Peplin (ASX:PEP) at the company's annual general meeting. He was appointed as Deloitte Touche Tohmatsu's national chairman in June and is retiring as a Peplin director due to increased work commitments.
ResMed (ASX:RMD) has appointed US-based MediaFLO's CEO and president Richard Sulpizio as a director, replacing Christopher Bartlett, Professor Emertius of business administration at Harvard Business School.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
